Skip to main content

Home/ Pharmaceutical Laboratory/ Group items tagged abbott

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
hamelinclara

2012 in reflection : Article : Nature Reviews Drug Discovery - 1 views

www.nature.com/...nrd3927.html

Patent

shared by hamelinclara on 09 Jan 13 - No Cached
  • Last year saw the largest loss of revenue yet from major drugs due to patent expiries, but a continuation of 2011's higher level of drug approvals and new initiatives to address R&D challenges provide hope for the future.
  • In September 2012, the non-profit TransCelerate BioPharma was established by Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi, initially to focus on improving clinical trial processes.
  • Incentives to develop breakthrough products were one of the major themes in the fifth incarnation of the US Prescription Drug User Fee Act (PDUFA), authorized in July 2012, through which industry pays fees to the FDA for product review (Nature Rev. Drug Discov. 11, 586–588; 2012).
hamelinclara

Ten Pharmaceutical Companies Unite to Accelerate Development of New Medicines -- PHILAD... - 1 views

www.prnewswire.com/...f-new-medicines-170329346.html

Pharma Research TransCelerate

shared by hamelinclara on 09 Jan 13 - No Cached
  • Ten leading biopharmaceutical companies announced today that they have formed a non-profit organization to accelerate the development of new medicines. Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech a member of the Roche Group, and Sanofi launched TransCelerate BioPharma Inc. ("TransCelerate"), the largest ever initiative of its kind, to identify and solve common drug development challenges with the end goals of improving the quality of clinical studies and bringing new medicines to patients faster.
  • financial and other resources, including personnel, to solve industry-wide challenges in a collaborative environment.
  • among the heads of R&D at major pharmaceutical companies that there is a critical need to substantially increase the number of innovative new medicines,
  • ...2 more annotations...
  • As shared solutions in clinical research and other areas are developed, TransCelerate will involve industry alliances including Clinical Data Interchange Standards Consortium (CDISC), Critical-Path Institute (C-Path), Clinical Trials Transformation Initiative (CTTI), Innovative Medicines Initiative (IMI), regulatory bodies including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), and Contract Research Organizations (CROs).
  • "We applaud the companies in TransCelerate BioPharma for joining forces to address a series of longstanding challenges in new drug development. This collaborative approach in the pre-competitive arena, utilizing the collective experience and resources of 10 leading drug companies and others to follow, has the promise to lead to new paradigms and cost savings in drug development, all of which would strengthen the industry and its ability to develop innovative and much-needed therapies for patients.
hamelinclara

3 Pharma Stocks You Will Love In 2013 - Seeking Alpha - 0 views

seekingalpha.com/...a-stocks-you-will-love-in-2013

2013 stock pharma abbott bristol

shared by hamelinclara on 19 Feb 13 - No Cached
  • a new publicly traded company AbbVie Incorporated (ABBV).
  • XIENCE, ABSORB and MitraClip should drive the growth.
  • This system is extremely beneficial for people suffering from complex coronary anatomy
1 - 3 of 3
Showing 20▼ items per page